IGI Logo

Neulasta (Pegfilgrastim) has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020). This is a very good approval for lupin limited. Neulasta has a very big market in the USA. This is one of the significant achievements for the company this year, For Lupin oncology was a focused area for a long time and biologic is a perfect opportunity for Lupin limited. Neulasta (Pegfilgrastim) is the first biosimilar filing for lupin in USA market, we expect it will take a good amount of time for Lupin to launch the drug but its very positive for the company to get the acceptance of Neulasta (Pegfilgrastim).

Above views are of the author and not of the website kindly read disclaimer